Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLAzosentan and SAireito Study in Subarachnoid Hemorrhage (CLASS-SAH)
jRCTs031260324Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in subarachnoid hemorrhage (SAH) comparing Saireito + clazosentan with Placebo + clazosentan (2 arms). Primary endpoint: Primary: Pleural effusion detected by ultrasonography. Started Jul 2026; status: recruiting.
02
Drugs
saireito
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on jRCTs031260324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260324.